Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT02905357
Active, not recruiting Observational

Heart Attack Research Program- Imaging Study

NCT02905357 · tracked via the Priya Life Science Canada tracker
Phase
Observational
Started
2016-09-12
Last updated
2026-03-19

Condition(s) studied

Myocardial Infarction

Investigational drug(s) / intervention(s)

OCTCMR

OCT: Optical Coherence Tomography (OCT): Intracoronary imaging for amount and type of plaque as well as plaque rupture, ulceration, dissection and/or thrombosis.

CMR: Cardiac Magnetic Resonance Imaging (CMR): MRI of the heart to identify areas of infarction (damage) and/or edema (swelling).

Study summary

The HARP study is a multi-center, diagnostic observational study employing standardized imaging protocols in patients with MINOCA (MI with Non Obstructive Coronary Arteries) to determine the underlying diagnosis in each participant. Participants will be followed for recurrent clinical events, every 6 months, for a maximum of 10 years.

Eligibility

Sex
ALL
Min age
21 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria: * Acute ischemic symptoms compatible with diagnosis of MI, such as chest pain or anginal equivalent symptoms at rest or new onset exertional anginal equivalent symptoms * Objective evidence of MI (either or both of the following): * Elevation of troponin to above the laboratory upper limit of normal * ST segment elevation of ≥1mm on 2 contiguous ECG leads * Willing to provide informed consent and comply with all aspects of the protocol * Age ≥ 21 years Exclusion Criteria: * Stenosis ≥50% of any major epicardial vessel on invasive angiography, as determined by the angiographer at the time of clinically ordered cardiac catheterization * History of known obstructive coronary artery disease at angiography, including history of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) * Recent use of vasospastic agents, such as cocaine, triptans, or ergot alkaloids (≤1 month) * Alternate explanation for troponin elevation, such as hypertensive urgency, acute exacerbation of heart failure, chronic elevation due to kidney disease, pulmonary embolism, cardiac trauma * Coronary dissection apparent on angiography * Excessive coronary tortuosity which, in the angiographer's opinion, increases the risks of OCT * eGFR\<45 or contraindication to additional contrast needed for OCT in the opinion of the angiographer or treating physician * Contraindication to MRI (including but not limited to ferromagnetic implants) * Pregnancy * Thrombolytic therapy for STEMI (qualifying event)

Primary outcome measure(s)

Trial sites (20)

FacilityCityRegionStatus
University of Alabama-Birmingham Birmingham Alabama
Cedars-Sinai Medical Center Los Angeles California
UC San Diego Medical Center San Diego California
Stanford University Stanford California
University of Florida Medical Center Gainesville Florida
Emory University Atlanta Georgia
Johns Hopkins Medical Center Baltimore Maryland
Dartmouth-Hitchcock Lebanon New Hampshire
NYU Winthrop Mineola New York
NYU Langone Medical Center New York New York
Columbia University Medical Center/NYPH New York New York
Ohio State University Medical Center Columbus Ohio
St. Luke's University Health Network Bethlehem Pennsylvania
University of Pittsburgh Medical Center Pittsburgh Pennsylvania
Seton Heart (Ascension) Univeristy of Austin, Texas Austin Texas
University of Alberta Edmonton Alberta
Vancouver General Hospital Vancouver British Columbia
St. Boniface General Hospital Winnipeg Manitoba
University of Calgary Calgary Canada
Golden Jubilee National Hospital Clydebank Scotland

More NYU Langone Health trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02905357 on ClinicalTrials.gov ↗ ← All trials in Canada